厄洛替尼联合吉西他滨治疗晚期胰腺癌疗效观察

目的观察厄洛替尼联合吉西他滨治疗晚期胰腺癌的疗效及安全性。方法将晚期胰腺癌患者42例随机分为观察组20例和对照组22例。观察组给予厄洛替尼联合吉西他滨治疗;对照组给予吉西他滨治疗,2组均以21d为1个疗程。比较2组临床疗效及不良反应。结果观察组有效率(RR)、疾病控制率(DCR)分别为10.0%、65.0%,高于对照组的4.5%、50.0%;观察组PFS、OS分别为3.6、6.1个月,长于对照组的3.1、5.2个月,差异均有统计学意义(P<0.05)。2组不良反应主要为皮疹、腹泻、骨髓抑制、恶心、呕吐、乏力等。结论厄洛替尼联合吉西他滨治疗晚期胰腺癌有一定疗效,耐受性好,值得进一步扩大样本研究。

Clinical effect of Erlotinib plus gemdtabine in treatment of advanced pancreas cancer

Objective To evaluate the efficacy and safety of Erlotinib plus gemcitabine in treatment of advanced pan- creas cancer. Mehteds 42 patients were randomly divided into observation group （ n = 20） and control group （ n = 22）. The observation group received Erlotinib plus Gemcitabine,while the control group was given with Gemcitabine. 21d were a course of treatment in both group, and clinical efficacy and adverse reactions in the two groups were compared. Results RR and DCR in the observation group were 10.0% and 65.0% ,which were higher than 4.5% and 50. 0% in the control group;PFS and OS in the observation group were respectively 3.6 and 6.1 months, which were longer than 3.1 and 5.2 months in the con- trol group, the differences were statistically significant （P 〈 0.05 ）. The main side effects were rash, diarrhea, bone marrow sup- pression, nausea,vomiting and fatigue in the two groups. Conclusion Erlotinib plus gemcitabine in advanced pancreas cancer is an effective therapy for the patients with advanced pancreas cancer and the toxicities can be tolerated, and it is worthy of fur- ther expansion of the sample studied.